A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2019-07-16
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety and efficacy of GDC-0853 in combination with standard
of care therapy in participants with moderate to severe active systemic lupus erythematosus
(SLE).